Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $19.10 USD
Change Today +0.10 / 0.53%
Volume 187.1K
EPZM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

epizyme inc (EPZM) Snapshot

Open
$19.04
Previous Close
$19.00
Day High
$19.47
Day Low
$18.73
52 Week High
08/14/14 - $40.98
52 Week Low
05/1/15 - $15.51
Market Cap
787.0M
Average Volume 10 Days
223.9K
EPS TTM
$-3.17
Shares Outstanding
41.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EPIZYME INC (EPZM)

epizyme inc (EPZM) Related Businessweek News

No Related Businessweek News Found

epizyme inc (EPZM) Details

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. Its proprietary product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases (HMTs). The company has two HMTs inhibitors in clinical development for the treatment of patients with cancers. It is conducting a Phase I/II clinical trial of EPZ-6438, an inhibitor that targets the EZH2 HMT for the treatment of non-Hodgkin lymphoma and advanced solid tumors, including INI1-deficient tumors, such as synovial sarcoma and malignant rhabdoid tumors; and two Phase 1 clinical trials of EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemia with genetic alterations of the MLL gene. It has therapeutic collaborations with Celgene Corporation and Celgene International Sàrl; Eisai Co., Ltd.; and Glaxo Group Limited., as well as companion diagnostic development collaborations with Roche Molecular Systems, Inc. and Abbott Molecular Inc. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

86 Employees
Last Reported Date: 03/12/15
Founded in 2007

epizyme inc (EPZM) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: $652.8K
Chief Scientific Officer and President of Res...
Total Annual Compensation: $531.7K
Chief Development Officer
Total Annual Compensation: $163.7K
Compensation as of Fiscal Year 2014.

epizyme inc (EPZM) Key Developments

Epizyme Seeks Acquisitions

Epizyme, Inc. (NasdaqGS:EPZM) intends to use the net proceeds from the sale of any securities offered under this prospectus to fund clinical development of our product candidates, to fund preclinical development and research to advance our pipeline and expand our product platform and for general corporate purposes unless otherwise indicated in the applicable prospectus supplement. General corporate purposes may include the acquisition of companies or businesses, repayment and refinancing of debt, if any, working capital and capital expenditures.

Epizyme, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Epizyme, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported collaboration revenue of $911,000 against $13,391,000 a year ago. Operating loss was $61,377,000 against $6,912,000 a year ago. Net loss was $61,326,000 or $1.75 per basic and diluted share against $6,884,000 or $0.22 per basic and diluted share a year ago. The decline in collaboration revenue primarily reflects the substantial completion of certain components of the company’s research obligations under its collaborations.

Epizyme, Inc. to Report Q1, 2015 Results on Apr 28, 2015

Epizyme, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on Apr 28, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EPZM:US $19.10 USD +0.10

EPZM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EPZM.
View Industry Companies
 

Industry Analysis

EPZM

Industry Average

Valuation EPZM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 23.1x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIZYME INC, please visit www.epizyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.